On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

Earnings per share excluding some items surged to $2.09, Astra said Thursday, higher than the $2.04 estimated by analysts ...

The US Food and Drug Administration (FDA) has granted breakthrough device designation for Acrivon Therapeutics’ ACR-368 ...

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...

The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with ...

The ACR-368-tailored OncoSignature assay is being used to predict patients most likely to respond to ACR-368 in Acrivon’s ongoing, registrational-intent, multicenter Phase 2b trial of ACR-368 in ...

A small, early trial of a vaccine that mobilizes the immune system to battle advanced kidney cancers appears successf ...

New research from Emory University and international organizations could be a breakthrough in treating childhood brain cancer ...

A group of 18 colorectal cancer patients experienced complete remission after taking the experimental drug dostarlimab for ...

Less than two months after an accelerated approval from the FDA, a drug combination featuring Pfizer’s Braftovi has turned in ...

University of Illinois Chicago scientists have redesigned a treatment for the most common pediatric leukemia to eliminate its ...

The results could sway U.S. regulators to convert Braftovi’s accelerated clearance in colorectal tumors into a full approval ...